Microsoft, weight loss drug sales, and GSK profits surge

Business

In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Dell and Palantir to join S&P 500; shares of both jump
The companies and organisations named and shamed in Grenfell report
Google’s second antitrust trial could help shape the future of online ads
Starlink in Brazil’s crosshairs as spat over Elon Musk’s X escalates
SA Rugby apologises for Joburg haka ‘mistake’